Quote this publication Share Print

TALTZ (ixekizumab), immunosuppressive interleukin IL-17A inhibitor

DERMATOLOGY - New medicinal product
Opinions on drugs - Posted on Jan 26 2017

Reason for request

Inclusion

No clinical advantage demonstrated relative to COSENTYX.

  • TALTZ has Marketing Authorisation in the treatment of moderate to severe plaque psoriasis in adults who require systemic therapy.
  • Its superiority to ENBREL (etanercept) and to STELARA (ustekinumab) has been demonstrated, but it has not been compared to COSENTYX (sekukinumab), another IL-17A inhibitor.
  • TALTZ should be reserved for the treatment of plaque psoriasis in adults, in patients with severe chronic plaque psoriasis, defined by a failure (insufficient response, contraindication or intolerance) in at least two treatments including nonbiologic systemic treatments and phototherapy AND an extensive form and/or substantial psychosocial impact.

 

 


Clinical Benefit

Substantial

-

Insufficient

Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments